newsfilter
← Latest News
PR Newswire·

Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases

Adagrasib is the first and only KRASG12C inhibitor to prospectively demonstrate intracranial (IC) activity in KRASG12C-mutated NSCLC with untreated CNS metastases Data demonstrate compelling clinical activity;